中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
33期
19-21
,共3页
陈瑞%张爱荣%赵信喜%李战华
陳瑞%張愛榮%趙信喜%李戰華
진서%장애영%조신희%리전화
黏膜皮肤淋巴结综合征%基质金属蛋白酶2%基质金属蛋白酶9%免疫球蛋白G%治疗
黏膜皮膚淋巴結綜閤徵%基質金屬蛋白酶2%基質金屬蛋白酶9%免疫毬蛋白G%治療
점막피부림파결종합정%기질금속단백매2%기질금속단백매9%면역구단백G%치료
Mueoeutaneous lymph node syndrome%Matrix metalloproteinase 2%Matrix metalloproteinase 9%Immunoglobulin G%Therapy
目的 冠状动脉探讨丙种球蛋白对川崎病患儿血清基质金属蛋白酶(MMP)-2及MMP-9检测的影响和临床意义,以积累经验,指导临床工作.方法 选取61例川崎病患儿,随机分为两组:对照组(16例)应用常规治疗;观察组(45例)在常规治疗的基础上加用丙种球蛋白,观察组患儿按有无冠状动脉损伤分为两组:冠状动脉损伤组(28例)和无冠状动脉损伤组(17例).检测治疗前和治疗后患儿血清MMP-2和MMP-9的变化.结果 对照组MMP-2和MMP-9治疗前后比较,差异均无统计学意义(P>0.05).观察组治疗前MMP-2和MMP-9[(266.4±88.0)、(443.5±113.4)μg/L]与治疗后[(181.8±46.4)、(254.9±113.4)μg/L]比较,差异均有统计学意义(P<0.05),观察组治疗后MMP-2和MMP-9与对照组治疗后比较,差异均有统计学意义(P<0.05).冠状动脉损伤组MMP-2、MMP-9减少值明显高于无冠状动脉损伤组,两组比较差异均有统计学意义(P<0.05).结论 丙种球蛋白能显著降低川崎病患儿血清MMP-2和MMP-9的表达,对减缓冠状细胞外基质的损伤有重要作用.
目的 冠狀動脈探討丙種毬蛋白對川崎病患兒血清基質金屬蛋白酶(MMP)-2及MMP-9檢測的影響和臨床意義,以積纍經驗,指導臨床工作.方法 選取61例川崎病患兒,隨機分為兩組:對照組(16例)應用常規治療;觀察組(45例)在常規治療的基礎上加用丙種毬蛋白,觀察組患兒按有無冠狀動脈損傷分為兩組:冠狀動脈損傷組(28例)和無冠狀動脈損傷組(17例).檢測治療前和治療後患兒血清MMP-2和MMP-9的變化.結果 對照組MMP-2和MMP-9治療前後比較,差異均無統計學意義(P>0.05).觀察組治療前MMP-2和MMP-9[(266.4±88.0)、(443.5±113.4)μg/L]與治療後[(181.8±46.4)、(254.9±113.4)μg/L]比較,差異均有統計學意義(P<0.05),觀察組治療後MMP-2和MMP-9與對照組治療後比較,差異均有統計學意義(P<0.05).冠狀動脈損傷組MMP-2、MMP-9減少值明顯高于無冠狀動脈損傷組,兩組比較差異均有統計學意義(P<0.05).結論 丙種毬蛋白能顯著降低川崎病患兒血清MMP-2和MMP-9的錶達,對減緩冠狀細胞外基質的損傷有重要作用.
목적 관상동맥탐토병충구단백대천기병환인혈청기질금속단백매(MMP)-2급MMP-9검측적영향화림상의의,이적루경험,지도림상공작.방법 선취61례천기병환인,수궤분위량조:대조조(16례)응용상규치료;관찰조(45례)재상규치료적기출상가용병충구단백,관찰조환인안유무관상동맥손상분위량조:관상동맥손상조(28례)화무관상동맥손상조(17례).검측치료전화치료후환인혈청MMP-2화MMP-9적변화.결과 대조조MMP-2화MMP-9치료전후비교,차이균무통계학의의(P>0.05).관찰조치료전MMP-2화MMP-9[(266.4±88.0)、(443.5±113.4)μg/L]여치료후[(181.8±46.4)、(254.9±113.4)μg/L]비교,차이균유통계학의의(P<0.05),관찰조치료후MMP-2화MMP-9여대조조치료후비교,차이균유통계학의의(P<0.05).관상동맥손상조MMP-2、MMP-9감소치명현고우무관상동맥손상조,량조비교차이균유통계학의의(P<0.05).결론 병충구단백능현저강저천기병환인혈청MMP-2화MMP-9적표체,대감완관상세포외기질적손상유중요작용.
Objective To observe the expressions of matrix metalloproteinase (MMP)-2 and MMP-9, explore their clinical significance in patients with Kawasaki disease by gamma globulin treatment, for accumulating clinical experience and directing the clinical work. Methods Sixty-one patients with Kawasaki disease were divided into two groups, the observation group (45 cases) were treated by gamma globulin, the control group (16 cases) were treated by routine treatment. The observation group was divided into the cardiovascular damage group (28 cases) and the non-cardiovascular damage group (17 cases). MMP-2 and MMP-9 were detected in the pre-treatment and post-treatment. Results There were no significant difference in the expressions of MMP-2 and MMP-9 between the pre-treatment and post-treatment in the control group (P >0.05). The expressions of MMP-2 and MMP-9 were obviously lower in the post-treatment [(181.8 ± 46.4), (254.9 ± 113.4)μg/L]than those in the pre-treatment [(266.4 ± 88.0),(443.5 ± 113.4)μg/L]in the observation group (P <0.05). There were significant difference in the expressions of MMP-2 and MMP-9 in the post-treatment between the observation group and the control group (P < 0.05). The decrease value of MMP-2 and MMP-9 were higher in the cardiovascular damage group than those in the non-cardiovascular damage group (P < 0.05). Conclusions The treatment of gamma globulin can decrease the expressions of MMP-2 and MMP-9 in Kawasaki disease. The gamma globulin may be value to reduee the extracellular matrix injury of Kawasaki disease.
